A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

NCT ID: NCT04857307

Last Updated: 2022-06-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-28
• Study Completion Date: 2022-04-05

Brief Summary

The purpose of the study is to assess the pharmacokinetics (PK), tolerability, and safety of Staccato alprazolam in adolescent study participants with epilepsy following single-dose administration.

Conditions

Epilepsy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Staccato alprazolam

The study participants will receive a single dose of Staccato alprazolam.

Group Type: EXPERIMENTAL

Alprazolam

Intervention Type: DRUG

• Pharmaceutical form: Inhalation powder.
• Study participants will receive Staccato alprazolam at prespecified time-points.

Interventions

Alprazolam

• Pharmaceutical form: Inhalation powder.
• Study participants will receive Staccato alprazolam at prespecified time-points.

Intervention Type: DRUG

Other Intervention Names

UCB7538

Eligibility Criteria

Inclusion Criteria

• Participant must be 12 to 17 years of age inclusive, at the time of signing the Informed Consent form (ICF) and the Assent form
• Participant has an established diagnosis of focal, generalized, or focal and generalized epilepsy
• Participant is in good general health as determined by medical evaluation including medical history and physical examination
• Participants with a body weight ≥29 kg and body mass index (BMI) within the range 14 to 32 kg/m^2 (inclusive)
• A male participant must agree to use contraception
• A female participant is eligible to participate if she is not pregnant
• Participant is capable of and provides assent, and the study participant's parent/legal representative provides signed informed consent for minor study participants, which includes compliance with the requirements and restrictions listed in the ICF, Assent form, and in this protocol
• Participant has a lifetime history of never smoking >5 cigarettes/day, and a current history (for at least 6 months prior to Screening Visit) of not smoking at all (including e-cigarette and vaping products)
• Participant has forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >80% predicted at Screening. In case of an out-of-range result, 1 repeat test will be allowed. If the readings are out-of-range again, the study participant will be excluded
• Participant is willing and able to be confined to a clinical research facility for up to 36 hours (including 1 overnight stay) and comply with the study schedule and study requirements.

Note: If there are no clinical contraindications, as per Investigator's judgment, study participants may leave the clinical research facility after the 6-hour postdose assessments and return to the clinic on Day 2 for the 24-hour and 36-hour postdose assessments

• Participant is currently taking at least 1 background antiepileptic drug (AED)
• Participant is able to actuate the training device during Screening, according to Instructions for Use

Exclusion Criteria

• Participant has history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, neurological, hematological, cerebrovascular, or other major disorders capable of significantly altering the absorption, metabolism, or elimination of Investigational Medicinal Product (IMP); constituting a risk when taking the study intervention; or interfering with the interpretation of data in the opinion of the Investigator
• Participant has a known hypersensitivity to any components of the IMP or comparative drugs (and/or an investigational device) as stated in the protocol
• Participant has severe chronic cardio-respiratory disease
• Participant has history of acute narrow angle glaucoma, hydrocephalus, or Myasthenia Gravis
• Participant has history or has current airway disease such asthma, cystic fibrosis, or chronic obstructive pulmonary disease
• Participant has any acute respiratory signs/symptoms (ie, wheezing) and active acute respiratory infection (or within 1 week of dosing) with exception of symptoms of mild rhinitis
• Participant has a known hypersensitivity to albuterol or similar short-acting beta2-agonist (SABA) that may be used as rescue medication administered in response to potential bronchospasm
• Participant is taking strong liver inducing agents (eg, phenytoin, phenobarbital, carbamazepine, and primidone) or strong Cytochrome P450 3A4 (CYP3A4) inhibitors
• Participant has a SpO2 measured by pulse oximetry <95% for >30 seconds during the Screening Visit

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

UCB Biopharma SRL

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

UCB Cares

Role: STUDY_DIRECTOR

001 844 599 2273 (UCB)

Locations

Up0100 102

Little Rock, Arkansas, United States

Up0100 110

Orlando, Florida, United States

Up0100 103

Honolulu, Hawaii, United States

Up0100 101

Bethesda, Maryland, United States

Up0100 108

Rochester, New York, United States

Up0100 106

Cincinnati, Ohio, United States

Up0100 105

Memphis, Tennessee, United States

Up0100 107

Tacoma, Washington, United States

Countries

United States

Other Identifiers

UP0100

Identifier Type: -

Identifier Source: org_study_id